Frequently Asked Questions
For Providers
Physicians value MCD’s clarity and efficiency. With the introduction of AI in the last 2-3 years,
there has been a huge increase in interest in MCD. At the American Society of Clinical
Oncology annual meeting in 2025, 20 out of 21 participants in our focus group said they would
pay to use MCD.
Our previously published research (Journal of Biomedical Informatics) demonstrated that providers prefer MCD, citing faster and more accurate recognition of critical results compared to standard EHR systems.
MCD is clinician-designed, peer-reviewed, and patented—with physician satisfaction at its core.
Our previously published research (Journal of Biomedical Informatics) demonstrated that providers prefer MCD, citing faster and more accurate recognition of critical results compared to standard EHR systems.
MCD is clinician-designed, peer-reviewed, and patented—with physician satisfaction at its core.
Frequently Asked Questions
For EHR Partners
MCD is EHR-agnostic and API-ready, designed to fit into existing ecosystems.
- FHIR and HL7 compatible
- Built for desktop, tablet, and mobile
- Works with current systems (labs, messaging, portals)
- Plugin-ready for EHR app marketplaces
Frequently Asked Questions
General Questions
Yes. However, our first task is to successfully integrate MCD into provider practices and EHRs.
Clinicians must trust and adopt MCD before extending it to patients. Once integrated into
practice, MCD can expand outward, potentially supported by liaison staff who triage
questions—similar to how medical scribes were first used in the ER.
In our surveys, patients strongly preferred having access to results through an interface like MCD compared to a standard portal. Patients said it helped them feel more informed and confident in their care.
In our surveys, patients strongly preferred having access to results through an interface like MCD compared to a standard portal. Patients said it helped them feel more informed and confident in their care.

My Critical Display ®2022 | All Rights Reserved